{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-032502","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-10-13T12:36:31+00:00","discovered_at":"2026-10-13T12:40:00.275520+00:00","generated_at":"2026-10-13T12:40:14.834360+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CervoMed reports Phase 2a nfvPPA data: plasma NfL fell ~3.1 pg/mL over 12 weeks; 24-week data Nov 2026","bullets":["Open-label Phase 2a in nfvPPA (NCT07033481): 25 participants; neflamapimod 40 mg TID (n=19) or 80 mg BID (n=6) for 24 weeks, then 12-week randomized withdrawal.","Baseline: 18/25 (72%) had elevated NfL; mean NfL 45.7 pg/mL (SD 39.6); 4/25 (16%) elevated GFAP, mean 103.4 pg/mL (SD 43.2).","Mean plasma NfL fell ~3.1 pg/mL over 12 weeks; in 13 participants with baseline NfL at/above median, mean reduction was ~5.7 pg/mL. GFAP stable.","Neflamapimod generally well tolerated; one patient with elevated liver enzymes met discontinuation criteria, asymptomatic, resolved after stopping; no new safety signals.","24-week biomarker data to be presented at CTAD in November 2026; topline clinical data expected Q1 2027. nfvPPA has no approved US/EU treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-032502","json":"https://secwatch.observer/filing/0001437749-26-032502.json","markdown":"https://secwatch.observer/filing/0001437749-26-032502.md","text":"https://secwatch.observer/filing/0001437749-26-032502.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/0001437749-26-032502-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926032502/crvo20261012_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-13T12:40:14.834360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}